Cargando…
Good Response of Advanced Thymic Carcinoma with Low PD-L1 Expression to Chemotherapy plus Pembrolizumab as First-Line Therapy and to Pembrolizumab as Maintenance Therapy: A Case Report
Thymic carcinoma is a rare malignant tumor with a poor prognosis. No standard treatment is currently available. The present case was a 64-year-old male smoker with no symptoms referred to our hospital because of abnormal chest radiological findings. The CT study showed a tumor between the anterior m...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9319623/ https://www.ncbi.nlm.nih.gov/pubmed/35890187 http://dx.doi.org/10.3390/ph15070889 |
_version_ | 1784755594915217408 |
---|---|
author | Nishii, Yoichi Furuhashi, Kazuki Ito, Kentaro Sakaguchi, Tadashi Suzuki, Yuta Fujiwara, Kentaro Yasuma, Taro Kobayashi, Tetsu D’Alessandro-Gabazza, Corina N. Gabazza, Esteban C. Taguchi, Osamu Hataji, Osamu |
author_facet | Nishii, Yoichi Furuhashi, Kazuki Ito, Kentaro Sakaguchi, Tadashi Suzuki, Yuta Fujiwara, Kentaro Yasuma, Taro Kobayashi, Tetsu D’Alessandro-Gabazza, Corina N. Gabazza, Esteban C. Taguchi, Osamu Hataji, Osamu |
author_sort | Nishii, Yoichi |
collection | PubMed |
description | Thymic carcinoma is a rare malignant tumor with a poor prognosis. No standard treatment is currently available. The present case was a 64-year-old male smoker with no symptoms referred to our hospital because of abnormal chest radiological findings. The CT study showed a tumor between the anterior mediastinum and the right lung upper lobe, multiple nodular shadows along the right pleura, and pleural effusion. A CT-guided needle biopsy revealed squamous cell carcinoma. However, the differential diagnosis between thymic carcinoma and primary lung cancer was difficult. Treatment with carboplatin, nanoparticle albumin-bound paclitaxel, and pembrolizumab was initiated. The CT scan showed tumor shrinkage and good clinical response after four treatment cycles. Therapy was switched to maintenance therapy with pembrolizumab alone. Imaging studies showed further tumor shrinkage after twelve cycles of maintenance therapy with pembrolizumab. Sixteen cycles of maintenance therapy were continued without performance status deterioration. An abnormal radiological finding was detected after a twelve-month exacerbation-free period. The diagnosis was thymic carcinoma. Treatment with lenvatinib was initiated, and tumor-size reduction was observed. This is the first report of a case showing a successful maintenance therapy with pembrolizumab after effective first-line therapy with a combination of carboplatin-based chemotherapy plus pembrolizumab in advanced thymic carcinoma. |
format | Online Article Text |
id | pubmed-9319623 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93196232022-07-27 Good Response of Advanced Thymic Carcinoma with Low PD-L1 Expression to Chemotherapy plus Pembrolizumab as First-Line Therapy and to Pembrolizumab as Maintenance Therapy: A Case Report Nishii, Yoichi Furuhashi, Kazuki Ito, Kentaro Sakaguchi, Tadashi Suzuki, Yuta Fujiwara, Kentaro Yasuma, Taro Kobayashi, Tetsu D’Alessandro-Gabazza, Corina N. Gabazza, Esteban C. Taguchi, Osamu Hataji, Osamu Pharmaceuticals (Basel) Case Report Thymic carcinoma is a rare malignant tumor with a poor prognosis. No standard treatment is currently available. The present case was a 64-year-old male smoker with no symptoms referred to our hospital because of abnormal chest radiological findings. The CT study showed a tumor between the anterior mediastinum and the right lung upper lobe, multiple nodular shadows along the right pleura, and pleural effusion. A CT-guided needle biopsy revealed squamous cell carcinoma. However, the differential diagnosis between thymic carcinoma and primary lung cancer was difficult. Treatment with carboplatin, nanoparticle albumin-bound paclitaxel, and pembrolizumab was initiated. The CT scan showed tumor shrinkage and good clinical response after four treatment cycles. Therapy was switched to maintenance therapy with pembrolizumab alone. Imaging studies showed further tumor shrinkage after twelve cycles of maintenance therapy with pembrolizumab. Sixteen cycles of maintenance therapy were continued without performance status deterioration. An abnormal radiological finding was detected after a twelve-month exacerbation-free period. The diagnosis was thymic carcinoma. Treatment with lenvatinib was initiated, and tumor-size reduction was observed. This is the first report of a case showing a successful maintenance therapy with pembrolizumab after effective first-line therapy with a combination of carboplatin-based chemotherapy plus pembrolizumab in advanced thymic carcinoma. MDPI 2022-07-19 /pmc/articles/PMC9319623/ /pubmed/35890187 http://dx.doi.org/10.3390/ph15070889 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Nishii, Yoichi Furuhashi, Kazuki Ito, Kentaro Sakaguchi, Tadashi Suzuki, Yuta Fujiwara, Kentaro Yasuma, Taro Kobayashi, Tetsu D’Alessandro-Gabazza, Corina N. Gabazza, Esteban C. Taguchi, Osamu Hataji, Osamu Good Response of Advanced Thymic Carcinoma with Low PD-L1 Expression to Chemotherapy plus Pembrolizumab as First-Line Therapy and to Pembrolizumab as Maintenance Therapy: A Case Report |
title | Good Response of Advanced Thymic Carcinoma with Low PD-L1 Expression to Chemotherapy plus Pembrolizumab as First-Line Therapy and to Pembrolizumab as Maintenance Therapy: A Case Report |
title_full | Good Response of Advanced Thymic Carcinoma with Low PD-L1 Expression to Chemotherapy plus Pembrolizumab as First-Line Therapy and to Pembrolizumab as Maintenance Therapy: A Case Report |
title_fullStr | Good Response of Advanced Thymic Carcinoma with Low PD-L1 Expression to Chemotherapy plus Pembrolizumab as First-Line Therapy and to Pembrolizumab as Maintenance Therapy: A Case Report |
title_full_unstemmed | Good Response of Advanced Thymic Carcinoma with Low PD-L1 Expression to Chemotherapy plus Pembrolizumab as First-Line Therapy and to Pembrolizumab as Maintenance Therapy: A Case Report |
title_short | Good Response of Advanced Thymic Carcinoma with Low PD-L1 Expression to Chemotherapy plus Pembrolizumab as First-Line Therapy and to Pembrolizumab as Maintenance Therapy: A Case Report |
title_sort | good response of advanced thymic carcinoma with low pd-l1 expression to chemotherapy plus pembrolizumab as first-line therapy and to pembrolizumab as maintenance therapy: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9319623/ https://www.ncbi.nlm.nih.gov/pubmed/35890187 http://dx.doi.org/10.3390/ph15070889 |
work_keys_str_mv | AT nishiiyoichi goodresponseofadvancedthymiccarcinomawithlowpdl1expressiontochemotherapypluspembrolizumabasfirstlinetherapyandtopembrolizumabasmaintenancetherapyacasereport AT furuhashikazuki goodresponseofadvancedthymiccarcinomawithlowpdl1expressiontochemotherapypluspembrolizumabasfirstlinetherapyandtopembrolizumabasmaintenancetherapyacasereport AT itokentaro goodresponseofadvancedthymiccarcinomawithlowpdl1expressiontochemotherapypluspembrolizumabasfirstlinetherapyandtopembrolizumabasmaintenancetherapyacasereport AT sakaguchitadashi goodresponseofadvancedthymiccarcinomawithlowpdl1expressiontochemotherapypluspembrolizumabasfirstlinetherapyandtopembrolizumabasmaintenancetherapyacasereport AT suzukiyuta goodresponseofadvancedthymiccarcinomawithlowpdl1expressiontochemotherapypluspembrolizumabasfirstlinetherapyandtopembrolizumabasmaintenancetherapyacasereport AT fujiwarakentaro goodresponseofadvancedthymiccarcinomawithlowpdl1expressiontochemotherapypluspembrolizumabasfirstlinetherapyandtopembrolizumabasmaintenancetherapyacasereport AT yasumataro goodresponseofadvancedthymiccarcinomawithlowpdl1expressiontochemotherapypluspembrolizumabasfirstlinetherapyandtopembrolizumabasmaintenancetherapyacasereport AT kobayashitetsu goodresponseofadvancedthymiccarcinomawithlowpdl1expressiontochemotherapypluspembrolizumabasfirstlinetherapyandtopembrolizumabasmaintenancetherapyacasereport AT dalessandrogabazzacorinan goodresponseofadvancedthymiccarcinomawithlowpdl1expressiontochemotherapypluspembrolizumabasfirstlinetherapyandtopembrolizumabasmaintenancetherapyacasereport AT gabazzaestebanc goodresponseofadvancedthymiccarcinomawithlowpdl1expressiontochemotherapypluspembrolizumabasfirstlinetherapyandtopembrolizumabasmaintenancetherapyacasereport AT taguchiosamu goodresponseofadvancedthymiccarcinomawithlowpdl1expressiontochemotherapypluspembrolizumabasfirstlinetherapyandtopembrolizumabasmaintenancetherapyacasereport AT hatajiosamu goodresponseofadvancedthymiccarcinomawithlowpdl1expressiontochemotherapypluspembrolizumabasfirstlinetherapyandtopembrolizumabasmaintenancetherapyacasereport |